Also known as: Krazati
Krazati is the brand name for adagrasib, an oral KRAS G12C-targeted oncology medicine. It is indicated as single-agent therapy in previously treated KRAS G12C-mutated advanced/metastatic NSCLC and in combination with cetuximab for similarly mutated advanced/metastatic colorectal cancer after prior chemotherapy. Initial U.S. approval was in 2022 and current U.S. indications are under accelerated approval.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
